{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:40:12Z","timestamp":1789501212358,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) remains a leading global cause of infectious mortality. Accelerating vaccine development requires validated immune correlates of protection (CoPs). Mechanistic studies have long highlighted Th1 cytokines (IFN-\u03b3, IL-2, TNF-\u03b1) as crucial for anti-mycobacterial immunity, leading to the hypothesis that antigen-specific Th1 responses, particularly polyfunctional T cells, may serve as a CoP. However, clinical evidence linking these responses to protection has been inconsistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis to evaluate antigen-specific IFN-\u03b3, IL-2, and TNF-\u03b1 as correlates of protection or risk. We searched PubMed\/MEDLINE, Embase, Web of Science, and Cochrane Central up to June 30, 2025. We included human studies with longitudinal follow-up that measured these cytokines and reported progression to active TB disease (primary analysis) or sustained IGRA conversion (secondary analysis). Study selection, data extraction, and risk-of-bias assessment were performed in duplicate. Random-effects meta-analyses were conducted where feasible, pooling across different antigen classes (e.g., PPD, BCG, ESAT-6\/CFP-10, vaccine antigens) and assay platforms (e.g., ICS, ELISpot, whole-blood). Although these assays and antigens differ in their ability to activate distinct immune responses, the pooled estimates reflect general trends in immune markers across various immunological contexts. This pooling approach was taken to maximize available data and evaluate broad immune responses. Where possible, we conducted subgroup and sensitivity analyses to explore the robustness of the findings across antigen and assay categories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 1, 268 records, 10 studies were included. In the primary analysis of active TB disease (n=6 studies), pooled odds ratios for IFN-\u03b3, IL-2, TNF-\u03b1, and polyfunctional responses were all close to 1.0 (range: 0.97\u20131.11) with confidence intervals spanning the null and low heterogeneity (I\u00b2 = 0%). In the secondary analysis of sustained IGRA conversion (n=5 studies), continuous measures of IFN-\u03b3 and IL-2 were marginally higher in converters (pooled MDs: 0.07 and 0.06, respectively). Binary analyses showed a consistent but modest trend toward positive association (pooled ORs: 1.13 for IFN-\u03b3, 1.07 for IL-2), though confidence intervals included 1.0. Sensitivity and subgroup analyses were conducted, including stratification by antigen type (e.g., PPD, BCG, ESAT-6\/CFP-10, vaccine antigens) and assay platform (e.g., ICS, ELISpot, whole-blood). While no significant effect modification was observed, this stratification underscores the importance of considering heterogeneity across different antigenic stimuli and assay methodologies when interpreting the pooled results. A Baujat plot identified specific studies (e.g., Kagina et\u00a0al., Nemes et\u00a0al.) as primary contributors to heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Available prospective evidence does not support antigen-specific Th1 cytokine magnitudes\u2014individually or as polyfunctional profiles\u2014as reliable, standalone correlates of protection against progression to active TB disease. These responses appear more strongly associated with immune activation states linked to recent antigen exposure or infection risk. The findings underscore the need to look beyond peripheral Th1 cytokine levels, recognizing that the pooled estimates across different antigen types and assay platforms reflect general directional trends rather than directly comparable quantitative effects. This highlights the need for a more nuanced approach, considering the diversity of immune responses induced by varying antigens and assay techniques. Future studies should aim for standardized, harmonized assays and endpoint definitions to allow for more accurate comparisons across different study designs and populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier INPLASY202610094.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1780600","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:40:49Z","timestamp":1771569649000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antigen-specific Th1 cytokine markers and protection against tuberculosis: a systematic review and meta-analysis stratified by progression to active disease and sustained IGRA conversion"],"prefix":"10.3389","volume":"16","author":[{"given":"TianYu","family":"Lin","sequence":"first","affiliation":[{"name":"Fuzong Clinical Medical College of Fujian Medical University","place":["Fuzhou, China"]},{"name":"The Second Department of Infection, 900th Hospital of PLA Joint Logistic Support Force","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[{"name":"The Second Department of Infection, 900th Hospital of PLA Joint Logistic Support Force","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Yu","family":"Pan","sequence":"additional","affiliation":[{"name":"The Second Department of Infection, 900th Hospital of PLA Joint Logistic Support Force","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17370","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Gu\u00e9rin vaccination against tuberculosis","volume":"17","author":"Abubakar","year":"2013","journal-title":"Health Technol. Assess."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107889","article-title":"BCG revaccination in adults enhances pro-inflammatory markers of trained immunity along with anti-inflammatory pathways","volume":"26","author":"Ahmed","year":"2023","journal-title":"iScience."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1086\/429994","article-title":"Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis","author":"Algood","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1128\/CVI.00721-14","article-title":"Quest for correlates of protection against tuberculosis","volume":"22","author":"Bhatt","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2012.07.010","article-title":"T cell assays and MIATA: the essential minimum for maximum impact","volume":"37","author":"Britten","year":"2012","journal-title":"Immunity."},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-010-0940-z","article-title":"Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond","volume":"60","author":"Britten","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12874-019-0687-y","article-title":"Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy","volume":"19","author":"Callegaro","year":"2019","journal-title":"BMC Med. Res. Methodol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/745483","article-title":"Role of TNF-alpha, IFN-gamma, and IL-10 in the development of pulmonary tuberculosis","volume":"2012","author":"Cavalcanti","year":"2012","journal-title":"Pulm Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.immuni.2009.10.007","article-title":"Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis","volume":"31","author":"Desvignes","year":"2009","journal-title":"Immunity."},{"key":"B10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1164\/rccm.200511-1783OC","article-title":"Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis","volume":"174","author":"Ewer","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11290","article-title":"T-cell activation is an immune correlate of risk in BCG vaccinated infants","volume":"7","author":"Fletcher","year":"2016","journal-title":"Nat. Commun."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.03154","article-title":"Clinical development of new TB vaccines: recent advances and next steps","volume":"10","author":"Hatherill","year":"2020","journal-title":"Front. Microbiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2009.09.007","article-title":"MIATA\u201d-minimal information about T cell assays","volume":"31","author":"Janetzki","year":"2009","journal-title":"Immunity."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e101224","DOI":"10.1371\/journal.pone.0101224","article-title":"The frequencies of IFN\u03b3+IL2+TNF\u03b1+ PPD-specific CD4+CD45RO+ T-cells correlate with the magnitude of the QuantiFERON\u00ae gold in-tube response in a prospective study of healthy Indian adolescents","volume":"9","author":"Jenum","year":"2014","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1164\/rccm.201003-0334OC","article-title":"Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Gu\u00e9rin vaccination of newborns","volume":"182","author":"Kagina","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869057","article-title":"The missing link in correlates of protective tuberculosis immunity: recognizing the infected cell","volume":"13","author":"Lewinsohn","year":"2022","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01262","article-title":"Polyfunctional CD4+ T cells as targets for tuberculosis vaccination","volume":"8","author":"Lewinsohn","year":"2017","journal-title":"Front. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/s41591-019-0441-3","article-title":"IFN-\u03b3-independent immune markers of Mycobacterium tuberculosis exposure","volume":"25","author":"Lu","year":"2019","journal-title":"Nat. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1307","DOI":"10.1016\/S2214-109X(22)00283-2","article-title":"Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis","volume":"10","author":"Martinez","year":"2022","journal-title":"Lancet Glob Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20180325","article-title":"Type I interferons in tuberculosis: Foe and occasionally friend","volume":"215","author":"Moreira-Teixeira","year":"2018","journal-title":"J. Exp. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.18609\/vac\/2022.027","article-title":"The quest for vaccine-induced immune correlates of protection against tuberculosis","volume":"1","author":"Nemes","year":"2022","journal-title":"Vaccine Insights"},{"key":"B23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","article-title":"The immune response in tuberculosis","volume":"31","author":"O\u2019Garra","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00992","article-title":"Lung tissue resident memory T-cells in the immune response to mycobacterium tuberculosis","volume":"10","author":"Ogongo","year":"2019","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa2412381","article-title":"BCG revaccination for the prevention of mycobacterium tuberculosis infection","volume":"392","author":"Schmidt","year":"2025","journal-title":"N Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(18)30421-3","article-title":"WHO preferred product characteristics for new vaccines against tuberculosis","volume":"18","author":"Schrager","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","article-title":"Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer","volume":"57","author":"Shouse","year":"2024","journal-title":"Immunity."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e37436","DOI":"10.1371\/journal.pone.0037436","article-title":"Correlation of mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary load in a high burden setting","volume":"7","author":"Theron","year":"2012","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41541-024-01004-w","article-title":"Immune correlates of protection as a game changer in tuberculosis vaccine development","volume":"9","author":"Wang","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B36","volume-title":"Global tuberculosis report 2024","year":"2024"},{"key":"B37","volume-title":"Tuberculosis \u2013 Fact sheet","year":"2025"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4110\/in.2024.24.e4","article-title":"TNF in human tuberculosis: A double-edged sword","volume":"24","author":"Yuk","year":"2024","journal-title":"Immune Netw."}],"updated-by":[{"DOI":"10.3389\/fcimb.2026.1838266","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000}}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1780600\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:48:03Z","timestamp":1783950483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1780600\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":38,"alternative-id":["10.3389\/fcimb.2026.1780600"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1780600","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"1780600"}}